27
Participants
Start Date
June 30, 2012
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
roflumilast
The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
placebo
The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
UAB Lung Health Center, Birmingham
University of Alabama at Birmingham
OTHER